Physician profile
Lalitha Ananth
NPI 1679597033
$7,940.31
in general payments reported to CMS, 2019-2025
24 companies · $30.35 in 2025
The $30.35 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $1,473 · 2021: $591 · 2022: $889 · 2023: $1,255 · 2024: $1,596 · 2025: $30.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.69 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,593.15 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,056.00 | 2019-2024 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $694.29 | 2019-2024 | Tremfya |
| Lilly USA, LLC | $677.50 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $646.11 | 2019-2023 | Krystexxa |
| Pfizer INC. | $437.42 | 2019-2024 | |
| Glaxosmithkline, LLC. | $412.22 | 2019-2024 | Benlysta |
| Radius Health, INC. | $240.27 | 2020-2024 | Tymlos |
| Aurinia Pharma U.S., INC. | $205.49 | 2022-2024 | Lupkynis |
| Genzyme Corporation | $140.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $133.52 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $111.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $111.03 | 2020-2024 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $109.20 | 2023-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.27 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $78.69 | 2019-2024 | Orencia |
| Celgene Corporation | $58.67 | 2019 | |
| Antares Pharma, INC. | $48.80 | 2019-2020 | |
| Ucb, INC. | $23.91 | 2024 | Cimzia |
| Sanofi-Aventis U.S. LLC | $17.58 | 2019 | |
| Medexus Pharma, INC. | $16.01 | 2019 | |
| Sentynl Therapeutics, INC. | $14.50 | 2019 | |
| Zyla Life Sciences, INC. | $12.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalitha Ananth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.